2. Search Result
Search Result
Results for "

GSDME

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Peptides

1

Natural
Products

1

Recombinant Proteins

1

Isotope-Labeled Compounds

3

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111770
    2-Bromohexadecanoic acid
    Maximum Cited Publications
    20 Publications Verification

    2-Bromopalmitic acid; 2-Bromopalmitate

    		 Pyroptosis Infection Inflammation/Immunology Cancer
    2-Bromohexadecanoic acid (2-Bromopalmitate; 2-BP) is a palmitoylation inhibitor targeting DHHC (Asp-His-His-Cys) protein palmitoyltransferase. 2-Bromohexadecanoic acid inhibits palmitoylation of GSDME-C during pyroptosis and inhibits BAK/BAX-Caspase 3-GSDME pathway-mediated pyroptosis .
    2-Bromohexadecanoic acid
  • HY-B0621
    Triclabendazole
    5+ Cited Publications

    CGA89317

    		 Parasite Caspase Bcl-2 Family PARP Pyroptosis Infection
    Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica .
    Triclabendazole
  • HY-P10939A
    Ac-DMLD-CMK TFA

    		Caspase Pyroptosis Inflammation/Immunology Cancer
    Ac-DMLD-CMK TFA is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DMLD-CMK TFA binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DMLD-CMK TFA alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .
    Ac-DMLD-CMK TFA
  • HY-RS05858
    GSDME Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    GSDME Human Pre-designed siRNA Set A contains three designed siRNAs for GSDME gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    GSDME Human Pre-designed siRNA Set A
    GSDME Human Pre-designed siRNA Set A
  • HY-RS16846
    Gsdme Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Gsdme Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gsdme gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gsdme Mouse Pre-designed siRNA Set A
    Gsdme Mouse Pre-designed siRNA Set A
  • HY-P10939
    Ac-DMLD-CMK

    		Caspase Pyroptosis Inflammation/Immunology Cancer
    Ac-DmLD-CMK is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DmLD-CMK binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DmLD-CMK alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .
    Ac-DMLD-CMK
  • HY-175381
    DeFer-2

    		PROTACs Pyroptosis Reactive Oxygen Species (ROS) Caspase Cancer
    DeFer-2 is a ferritin PROTAC degrader (Kd = 17.1 μM). DeFer-2 induces ferritin degradation, triggering caspase 3-GSDME-mediated pyroptosis in cancer cells through free iron accumulation and elevated ROS. DeFer-2 significantly inhibits tumor growth and prolongs survival in mice bearing B16F10 subcutaneous tumors. DeFer-2 can be used to study melanoma. (Pink: Oleic acid: HY-N1446, Blue: (S,R,S)-AHPC: HY-125845, Black: γ-Aminobutyric acid: HY-N0067, Blue + Black: (S,R,S)-AHPC-C3-NH2: HY-130711) .
    DeFer-2
  • HY-B0621R
    Triclabendazole (Standard)

    CGA89317 (Standard)

    		 Reference Standards Parasite Caspase Bcl-2 Family PARP Pyroptosis Infection
    Triclabendazole (Standard) is the analytical standard of Triclabendazole. This product is intended for research and analytical applications. Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica .
    Triclabendazole (Standard)
  • HY-N15380
    4,4′-Secalonic acid D

    		PARP Reactive Oxygen Species (ROS) Caspase Apoptosis Pyroptosis Cancer
    4,4′-Secalonic acid D (Compound 12) is a PARP1 inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting PARP1. 4,4′-Secalonic acid D has anti-tumor activity .
    4,4′-Secalonic acid D
  • HY-RS23287
    Gsdme Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Gsdme Rat Pre-designed siRNA Set A contains three designed siRNAs for Gsdme gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gsdme Rat Pre-designed siRNA Set A
    Gsdme Rat Pre-designed siRNA Set A
  • HY-B0621S
    Triclabendazole-d3

    CGA89317-d3

    		 Parasite Microtubule/Tubulin Isotope-Labeled Compounds Others
    Triclabendazole-d3 is the deuterium labeled Triclabendazole (HY-B0621). Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica .
    Triclabendazole-d3
  • HY-181005
    FGFR-IN-25

    		FGFR Akt PERK Reactive Oxygen Species (ROS) Caspase Pyroptosis PD-1/PD-L1 Neurological Disease Cancer
    FGFR-IN-25 (Compound 19E) is a FGFR inhibitor (IC50s: 1.30 nM and 0.85 nM for FGFR1 and FGFR2, respectively) and radiosensitizer. FGFR-IN-25 effectively reduces the phosphorylation of FGFR1 and its key downstream effectors, pAKT and pERK. FGFR-IN-25 exerts broad-spectrum antitumor activity against gastric cancer, colorectal carcinoma, hepatocellular carcinoma, breast cancer, triple-negative breast cancer, and glioblastoma. FGFR-IN-25, when combined with radiotherapy, synergistically activates the ROS-Caspase-3-GSDME axis, downregulates PD-L1 expression, and induces immunogenic cell death (ICD). FGFR-IN-25 combined with radiotherapy improves the antitumor efficacy .
    FGFR-IN-25

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: